© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 19, 1616-1634,
October 6, 1999
© 1999 Oxford University Press
REVIEW |
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
Affiliations of authors: J. E. Groopman, Harvard Medical School and the Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Boston, MA; L. M. Itri, Ortho Biotech Inc., Raritan, NJ.
Correspondence to: Jerome E. Groopman, M.D., Division of Experimental Medicine, Beth Israel Deaconess Medical Center, 4 Blackfan Circle, Suite 351, Boston, MA 02115.
Anemia is a common complication of myelosuppressive chemotherapy that results in a decreased functional capacity and quality of life (QOL) for cancer patients. Severe anemia is treated with red blood cell transfusions, but mild-to-moderate anemia in patients receiving chemotherapy has traditionally been managed conservatively on the basis of the perception that it was clinically unimportant. This practice has been reflected in the relative inattention to standardized and complete reporting of all degrees of chemotherapy-induced anemia. We undertook a comprehensive review of published chemotherapy trials of the most common single agents and combination chemotherapy regimens, including the new generation of chemotherapeutic agents, used in the treatment of the major nonmyeloid malignancies in adults to characterize and to document the incidence and severity of chemotherapy-induced anemia. Despite identified limitations in the grading and reporting of treatment-related anemia, the results confirm a relatively high incidence of mild-to-moderate anemia. Recent advances in assessing the relationships of anemia, fatigue, and QOL in cancer patients are providing new insights into these closely related factors. Clinical data are emerging that suggest that mild-to-moderate chemotherapy-induced anemia results in a perceptible reduction in a patient's energy level and QOL. Future research may lead to new classifications of chemotherapy-induced anemia that can guide therapeutic interventions on the basis of outcomes and hemoglobin levels. Perceptions by oncologists and patients that lesser degrees of anemia must be endured without treatment may be overcome as greater emphasis is placed on the QOL of the oncology patient and as research provides further insights into the relationships between hemoglobin levels, patient well-being, and symptoms.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. C Fullmer and R. Miller Retrospective review of hemoglobin and/or hematocrit levels with occurrence of thrombosis in cancer patients treated with erythropoiesis stimulating agents Journal of Oncology Pharmacy Practice, September 1, 2009; 15(3): 167 - 173. [Abstract] [PDF]
|
|
|
|
 |
|
 A. LATVALA, K. SYRJANEN, H. SALMENOJA, and E. SALMINEN Anaemia and Other Predictors of Fatigue Among Patients on Palliative Therapy for Advanced Cancer Anticancer Res, July 1, 2009; 29(7): 2569 - 2575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Scrijvers, F. Roila, and On behalf of the ESMO Guidelines Working Group Erythropoiesis-stimulating agents in cancer patients: ESMO Recommendations for use Ann. Onc., May 1, 2009; 20(suppl_4): iv159 - iv161. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Riva, M. Tettamanti, P. Mosconi, G. Apolone, F. Gandini, A. Nobili, M. V. Tallone, P. Detoma, A. Giacomin, M. Clerico, et al. Association of mild anemia with hospitalization and mortality in the elderly: the Health and Anemia population-based study Haematologica, January 1, 2009; 94(1): 22 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Courneya, L. W. Jones, C. J. Peddle, C. M. Sellar, T. Reiman, A. A. Joy, N. Chua, L. Tkachuk, and J. R. Mackey Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial Oncologist, September 1, 2008; 13(9): 1012 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Gordon, G. Nichols, A. Ben-Jacob, D. Tomita, T. Lillie, and C. Miller Treating Anemia of Cancer with Every-4-Week Darbepoetin Alfa: Final Efficacy and Safety Results from a Phase II, Randomized, Double-Blind, Placebo-Controlled Study Oncologist, June 1, 2008; 13(6): 715 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Barbour Caring for the treatment-experienced breast cancer patient: The pharmacist's role Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S16 - S22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pirker, R. A. Ramlau, W. Schuette, P. Zatloukal, I. Ferreira, T. Lillie, and J. F. Vansteenkiste Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide J. Clin. Oncol., May 10, 2008; 26(14): 2342 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Spaepen, N. Demarteau, S. Van Belle, and L. Annemans Health Economic Evaluation of Treating Anemia in Cancer Patients Receiving Chemotherapy: A Study in Belgian Hospitals Oncologist, May 1, 2008; 13(5): 596 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bastit, A. Vandebroek, S. Altintas, B. Gaede, T. Pinter, T. S. Suto, T. W. Mossman, K. E. Smith, and J. F. Vansteenkiste Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia J. Clin. Oncol., April 1, 2008; 26(10): 1611 - 1618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pedrazzoli, A. Farris, S. Del Prete, F. Del Gaizo, D. Ferrari, C. Bianchessi, G. Colucci, A. Desogus, T. Gamucci, A. Pappalardo, et al. Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa J. Clin. Oncol., April 1, 2008; 26(10): 1619 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dubsky, P. Sevelda, R. Jakesz, H. Hausmaninger, H. Samonigg, M. Seifert, U. Denison, B. Mlineritsch, G. Steger, W. Kwasny, et al. Anemia Is a Significant Prognostic Factor in Local Relapse-Free Survival of Premenopausal Primary Breast Cancer Patients Receiving Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil Chemotherapy Clin. Cancer Res., April 1, 2008; 14(7): 2082 - 2087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Velanovich Innovative Use of Quality-of-Life Data: Correlating Physiologic Parameters With Patient-Centered Symptoms-- The Example of Anemia on the Vitality of Surgical Oncology Patients Surgical Innovation, March 1, 2008; 15(1): 47 - 51. [Abstract] [PDF]
|
|
|
|
|
|
M. Aapro, R. C. Leonard, A. Barnadas, M. Marangolo, M. Untch, N. Malamos, J. Mayordomo, D. Reichert, J. L. Pedrini, L. Ukarma, et al. Effect of Once-Weekly Epoetin Beta on Survival in Patients With Metastatic Breast Cancer Receiving Anthracycline- and/or Taxane-Based Chemotherapy: Results of the Breast Cancer--Anemia and the Value of Erythropoietin (BRAVE) Study J. Clin. Oncol., February 1, 2008; 26(4): 592 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Muller and D. Baribeault Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia Am. J. Health Syst. Pharm., December 15, 2007; 64(24): 2547 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Charu, B. Saidman, A. Ben-Jacob, G. R. Justice, A. S. Maniam, D. Tomita, G. Rossi, T. Rearden, and J. Glaspy A Randomized, Open-Label, Multicenter Trial of Immediate Versus Delayed Intervention with Darbepoetin Alfa for Chemotherapy-Induced Anemia Oncologist, October 1, 2007; 12(10): 1253 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Spence Medical and economic impact of anemia in hospitalized patients Am. J. Health Syst. Pharm., August 15, 2007; 64(16_Supplement_11): S3 - S10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Charu, C. P. Belani, A. N. Gill, M. Bhatt, D. Tomita, G. Rossi, and A. Ben-Jacob Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial Oncologist, June 1, 2007; 12(6): 727 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Boccia, T. Lillie, D. Tomita, and L. Balducci The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Hematologic Outcomes and Quality of Life in Older Patients With Chemotherapy-Induced Anemia Oncologist, May 1, 2007; 12(5): 584 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Ryan, J. K. Carroll, E. P. Ryan, K. M. Mustian, K. Fiscella, and G. R. Morrow Mechanisms of Cancer-Related Fatigue Oncologist, May 1, 2007; 12(suppl_1): 22 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dmoszynska, J. Kloczko, M. Rokicka, A. Hellmann, I. Spicka, and J. E. Eid A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy Haematologica, April 1, 2007; 92(4): 493 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. DeBellis Introduction Am. J. Health Syst. Pharm., February 1, 2007; 64(3_Supplement_2): S3 - S4. [Full Text] [PDF]
|
|
|
|
|
|
R. N. Schwartz Anemia in patients with cancer: Incidence, causes, impact, management, and use of treatment guidelines and protocols Am. J. Health Syst. Pharm., February 1, 2007; 64(3_Supplement_2): S5 - S13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Morishima, M. Ogura, S. Yoneda, H. Sakai, K. Tobinai, Y. Nishiwaki, H. Minami, T. Hotta, K. Ezaki, Y. Ohe, et al. Once-Weekly Epoetin-Beta Improves Hemoglobin Levels in Cancer Patients with Chemotherapy-Induced Anemia: A Randomized, Double-Blind, Dose-Finding Study Jpn. J. Clin. Oncol., October 1, 2006; 36(10): 655 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Goram Every-three-week administration of darbepoetin alfa in women with chemotherapy-associated anemia. Am. J. Health Syst. Pharm., August 15, 2006; 63(16): 1522 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Fujisaka, T. Tamura, Y. Ohe, H. Kunitoh, I. Sekine, N. Yamamoto, H. Nokihara, A. Horiike, T. Kodama, and N. Saijo Pharmacokinetics and Pharmacodynamics of Weekly Epoetin Beta in Lung Cancer Patients Jpn. J. Clin. Oncol., August 1, 2006; 36(8): 477 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Glaspy, S. Vadhan-Raj, R. Patel, L. Bosserman, E. Hu, R. E. Lloyd, R. V. Boccia, D. Tomita, and G. Rossi Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: The 20030125 Study Group Trial J. Clin. Oncol., May 20, 2006; 24(15): 2290 - 2297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Boccia, I. A. Malik, V. Raja, S. Kahanic, R. Liu, T. Lillie, D. Tomita, B. Clowney, and P. Silberstein Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist, April 1, 2006; 11(4): 409 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D Killian, V. Gupta, and A. E Goetz Cost Analysis of Erythropoietic-Stimulating Therapy Dosing in Oncology Inpatients Ann. Pharmacother., March 1, 2006; 40(3): 421 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Canon, J. Vansteenkiste, G. Bodoky, M. V. Mateos, L. Bastit, I. Ferreira, G. Rossi, and R. G. Amado Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst, February 15, 2006; 98(4): 273 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Savonije, C. J. van Groeningen, L. W. Wormhoudt, and G. Giaccone Early Intervention with Epoetin Alfa During Platinum-Based Chemotherapy: An Analysis of Quality-of-Life Results of a Multicenter, Randomized, Controlled Trial Compared with Population Normative Data. Oncologist, February 1, 2006; 11(2): 197 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Savonije, C. J. van Groeningen, L. W. Wormhoudt, and G. Giaccone Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Oncologist, February 1, 2006; 11(2): 206 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Quirt, M. Kovacs, F. Couture, A. R. Turner, M. Noble, R. Burkes, S. Dolan, R. K. Plante, C. Y. Lau, J. Chang, et al. Patients Previously Transfused or Treated with Epoetin Alfa at Low Baseline Hemoglobin Are at Higher Risk for Subsequent Transfusion: An Integrated Analysis of the Canadian Experience Oncologist, January 1, 2006; 11(1): 73 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Engert Recombinant human erythropoietin in oncology: current status and further developments Ann. Onc., October 1, 2005; 16(10): 1584 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barrett-Lee, C. Bokemeyer, P. Gascon, J.W.R. Nortier, M. Schneider, D. Schrijvers, S. Van Belle, and for the Ecas Advisory Board and Participating Cent Management of Cancer-Related Anemia in Patients with Breast or Gynecologic Cancer: New Insights Based on Results from the European Cancer Anemia Survey Oncologist, October 1, 2005; 10(9): 743 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stasi, S. Amadori, T. J. Littlewood, E. Terzoli, A. C. Newland, and D. Provan Management of Cancer-Related Anemia with Erythropoietic Agents: Doubts, Certainties, and Concerns Oncologist, August 1, 2005; 10(7): 539 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Duh, P. Lefebvre, J. Fastenau, C. T. Piech, and R. J. Waltzman Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve Oncologist, June 1, 2005; 10(6): 438 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Leonard, M. Untch, and F. Von Koch Management of anaemia in patients with breast cancer: role of epoetin Ann. Onc., May 1, 2005; 16(5): 817 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Witzig, P. T. Silberstein, C. L. Loprinzi, J. A. Sloan, P. J. Novotny, J. A. Mailliard, K. M. Rowland, S. R. Alberts, J. E. Krook, R. Levitt, et al. Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy J. Clin. Oncol., April 20, 2005; 23(12): 2606 - 2617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Weiss and L. T. Goodnough Anemia of Chronic Disease N. Engl. J. Med., March 10, 2005; 352(10): 1011 - 1023. [Full Text] [PDF]
|
|
|
|
|
|
U. Reinhardt, A. Tulusan, R. Angermund, H. Lutz, and For The German Epoetin Alfa Study Group Increased Hemoglobin Levels and Improved Quality-of-Life Assessments During Epoetin Alfa Treatment in Anemic Cancer Patients: Results of a Prospective, Multicenter German Trial Oncologist, March 1, 2005; 10(3): 225 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Herrington, S. L. Davidson, D. K. Tomita, L. Green, R. E. Smith, and R. V. Boccia Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia Am. J. Health Syst. Pharm., January 1, 2005; 62(1): 54 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Couture, A.R. Turner, B. Melosky, L. Xiu, R.K. Plante, C.Y. Lau, and I. Quirt Prior Red Blood Cell Transfusions in Cancer Patients Increase the Risk of Subsequent Transfusions With or Without Recombinant Human Erythropoietin Management Oncologist, January 1, 2005; 10(1): 63 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Davis Hematology in palliative medicine American Journal of Hospice and Palliative Medicine, November 1, 2004; 21(6): 445 - 454. [Abstract] [PDF]
|
|
|
|
|
|
L. S. Schwartzberg, L. K. Yee, F. M. Senecal, V. Charu, D. Tomita, J. Wallace, and G. Rossi A Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia in Patients With Breast, Lung, or Gynecologic Cancer Oncologist, November 1, 2004; 9(6): 696 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Blackwell, P. Gascon, G. Sigounas, and L. Jolliffe rHuEPO and Improved Treatment Outcomes: Potential Modes of Action Oncologist, November 1, 2004; 9(suppl_5): 41 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Hudis, S. Van Belle, J. Chang, and K. Muenstedt rHuEPO and Treatment Outcomes: the Clinical Experience Oncologist, November 1, 2004; 9(suppl_5): 55 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Voelter, C. Schuhmacher, R. Busch, C. Peschel, J. R. Siewert, and F. Lordick Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer Ann. Thorac. Surg., September 1, 2004; 78(3): 1037 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Patton, T. Reeves, and J. Wallace Effectiveness of Darbepoetin Alfa Versus Epoetin Alfa in Patients with Chemotherapy-Induced Anemia Treated in Clinical Practice Oncologist, July 1, 2004; 9(4): 451 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cella, J. Kallich, A. McDermott, and X. Xu The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials Ann. Onc., June 1, 2004; 15(6): 979 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Iop, A. M. Manfredi, and S. Bonura Fatigue in cancer patients receiving chemotherapy: an analysis of published studies Ann. Onc., May 1, 2004; 15(5): 712 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Auerbach, H. Ballard, J. R. Trout, M. McIlwain, A. Ackerman, H. Bahrain, S. Balan, L. Barker, and J. Rana Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial J. Clin. Oncol., April 1, 2004; 22(7): 1301 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Henry, P. Bowers, M. T. Romano, and R. Provenzano Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine Arch Intern Med, February 9, 2004; 164(3): 262 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kirshner, M. Hatch, D. D. Hennessy, M. Fridman, and R. E. Tannous Anemia in Stage II and III Breast Cancer Patients Treated With Adjuvant Doxorubicin and Cyclophosphamide Chemotherapy Oncologist, February 1, 2004; 9(1): 25 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Henry The Evolving Role of Epoetin Alfa in Cancer Therapy Oncologist, February 1, 2004; 9(1): 97 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Weiss New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical Applications Oncologist, December 1, 2003; 8(90003): 18 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zeuner, F. Pedini, M. Signore, U. Testa, E. Pelosi, C. Peschle, and R. De Maria Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins Blood, July 1, 2003; 102(1): 87 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Nissenson, L. T. Goodnough, and R. W. Dubois Anemia: Not Just an Innocent Bystander? Arch Intern Med, June 23, 2003; 163(12): 1400 - 1404. [Full Text] [PDF]
|
|
|
|
|
|
D. Cella, D. Dobrez, and J. Glaspy Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes Ann. Onc., April 1, 2003; 14(4): 511 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Gordon Managing Anemia in the Cancer Patient: Old Problems, Future Solutions Oncologist, August 1, 2002; 7(4): 331 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Caggiano, R. E. Tannous, S. Gupta, and M. Fridman Chemotherapy-induced moderate to severe anemia in intermediate-grade non-Hodgkin's lymphoma patients Journal of Oncology Pharmacy Practice, June 1, 2002; 8(2-3): 73 - 80. [Abstract] [PDF]
|
|
|
|
|
|
B. Holzner, G. Kemmler, R. Greil, M. Kopp, A. Zeimet, M. Raderer, M. Hejna, S. Zochbauer, G. Krajnik, H. Huber, et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients Ann. Onc., June 1, 2002; 13(6): 965 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Golab, D. Olszewska, P. Mroz, K. Kozar, R. Kaminski, A. Jalili, and M. Jakobisiak Erythropoietin Restores the Antitumor Effectiveness of Photodynamic Therapy in Mice with Chemotherapy- induced Anemia Clin. Cancer Res., May 1, 2002; 8(5): 1265 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Glaspy, L. Degos, M. Dicato, and G. D. Demetri Comparable Efficacy of Epoetin Alfa for Anemic Cancer Patients Receiving Platinum- and Nonplatinum-Based Chemotherapy: A Retrospective Subanalysis of Two Large, Community-Based Trials Oncologist, April 1, 2002; 7(2): 126 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Caggiano, S. Gupta, R. E Tannous, M. Fridman, and W. B Carter Chemotherapy-induced moderate tolife-threatening anemia in early-stage breast cancer Journal of Oncology Pharmacy Practice, December 1, 2001; 7(4): 127 - 132. [Abstract] [PDF]
|
|
|
|
 |
|
 L. M. Itri Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy Nephrol. Dial. Transplant., December 1, 2001; 16(12): 2289 - 2293. [Full Text] [PDF]
|
|
|
|
|
|
J. Seidenfeld, M. Piper, C. Flamm, V. Hasselblad, J. O. Armitage, C. L. Bennett, M. S. Gordon, A. E. Lichtin, J. L. Wade III, S. Woolf, et al. Epoetin Treatment of Anemia Associated With Cancer Therapy: a Systematic Review and Meta-analysis of Controlled Clinical Trials J Natl Cancer Inst, August 15, 2001; 93(16): 1204 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Knobel, J. H. Loge, M. B. Lund, K./o. Forfang, O. Nome, and S. Kaasa Late Medical Complications and Fatigue in Hodgkin's Disease Survivors J. Clin. Oncol., July 1, 2001; 19(13): 3226 - 3233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sabbatini The Relationship between Anemia and Quality of Life in Cancer Patients Oncologist, June 1, 2000; 5(2008): 19 - 23. [Abstract] [Full Text] [PDF]
|
|